
DFTX Stock Forecast & Price Target
DFTX Analyst Ratings
Bulls say
Definium Therapeutics is developing a promising drug pipeline, with a late-stage candidate receiving FDA Breakthrough Therapy Designation for Generalized Anxiety Disorder (GAD). In addition, the company is exploring the potential of DT402 for the treatment of autism spectrum disorder (ASD), which was well-received by industry experts at a recent psychedelics conference. The company has a strong potential for sales and revenue growth with its lead drug DT120, and with the current positive market sentiment towards psychedelics, there is a possibility for upside in its valuation. However, the company remains focused on progressing its drug to market and does not currently have a sustainability plan in place. It may face challenges in securing patent protection for its drugs, but the company could rely on regulatory exclusivity to defend against generics.
Bears say
Definium Therapeutics is facing several potential risks, including a higher than expected net loss in its latest quarter and potential safety concerns with its experimental drug DT120. While the company has received FDA breakthrough designation for DT120 in anxiety and depression, there is a risk that early positive data may not be replicable in larger trials. Furthermore, the company faces challenges in manufacturing and commercializing a controlled substance like LSD. These risks may limit the company's market access and hinder its potential for commercial success.
This aggregate rating is based on analysts' research of Definium Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
DFTX Analyst Forecast & Price Prediction
Start investing in DFTX
Order type
Buy in
Order amount
Est. shares
0 shares